MENU
HLN
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

HLN stock forecast, quote, news & analysis

Haleon is one of the largest consumer health companies in the world... Show more

HLN
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for HLN with price predictions
Aug 13, 2026

HLN sees its Stochastic Oscillator climbs out of oversold territory

On August 05, 2026, the Stochastic Oscillator for HLN moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 42 instances where the indicator left the oversold zone. In of the 42 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HLN advanced for three days, in of 251 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 242 cases where HLN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for HLN moved out of overbought territory on July 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on August 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HLN as a result. In of 68 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for HLN turned negative on July 31, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 34 similar instances when the indicator turned negative. In of the 34 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HLN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

HLN broke above its upper Bollinger Band on July 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.950) is normal, around the industry mean (40.446). P/E Ratio (20.040) is within average values for comparable stocks, (93.276). Projected Growth (PEG Ratio) (2.424) is also within normal values, averaging (2.212). Dividend Yield (0.020) settles around the average of (0.032) among similar stocks. P/S Ratio (2.912) is also within normal values, averaging (114.156).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HLN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

A.I.Advisor
published Dividends

HLN is expected to pay dividends on September 17, 2026

Haleon plc HLN Stock Dividends
A dividend of $0.06 per share will be paid with a record date of September 17, 2026, and an ex-dividend date of August 14, 2026. The last dividend of $0.13 was paid on May 14. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -1%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 27%. BTAI experienced the highest price growth at 36%, while SXTC experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -18%. For the same stocks of the Industry, the average monthly volume growth was 25% and the average quarterly volume growth was -2%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 65
Price Growth Rating: 56
SMR Rating: 88
Profit Risk Rating: 83
Seasonality Score: -3 (-100 ... +100)
View a ticker or compare two or three
HLN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Profile
Details
Industry
N/A
Address
The Heights
Phone
+44 1932822000
Employees
25408
Web
https://www.haleon.com
HLN sees its Stochastic Oscillator climbs out of oversold territory